Skip to main content
Premium Trial:

Request an Annual Quote

New England Biolabs, TTP Partner to Provide MDx Development Services

NEW YORK (GenomeWeb) – New England Biolabs and TTP have established a non-exclusive partnership to offer services to molecular diagnostic technology developers.

Together, Ipswich, Massachusetts-based NEB and Cambridge, UK-based TTP will offer product-development services spanning instrumentation, consumables, and reagents.

More specifically, the partnership is focused on supporting customers in the MDx and wider life science space to "rapidly transition ideas into commercially successful products," the partners said.

The services will couple NEB's catalog of reagents and expertise in enzyme development and manufacturing with TTP's Desktop Biology product development and physical engineering know-how.

"At TTP, we understand the fundamental steps required to convert lab-based biological processes to a functional low-cost disposable and instrument, and together we are now able to fast track more complete product development solutions," Giles Sanders, consultant at TTP, said in a statement.

"NEB was already committed to developing novel enzyme specificities for incorporation into new clinical and molecular testing platforms," Breton Hornblower, product manager at NEB, said in a statement. "Our customers will now be able to access these reagents as part of these services, along with those of TTP."

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more